Diversified Healthcare Solutions
Providing world-class pharmaceutical products across Human Health, Veterinary Medicine, and Infection Control — backed by state-of-the-art manufacturing and rigorous quality standards.
Since its founding in 1994, Saudi Pharmaceutical Industries (SPI) has built a clear and unwavering mission: to become one of the leading pharmaceutical companies in the MENA region.
We provide a wide range of high-quality branded generic products across a diversified healthcare business model — spanning Human Health, Animal Health, and Infection Control.
Our high-standard manufacturing facilities in Riyadh and Sudair, Saudi Arabia, are equipped with modern automated machinery and certified with C-GMP, SFDA & ISO standards — a testament to our unwavering commitment to quality.
From a single vision to a multi-facility, multi-division pharmaceutical powerhouse — SPI's journey reflects a commitment to healthcare that transcends borders.
The principles that guide every decision, every product, and every relationship we build.
To become a leading and reliable pharmaceutical company with a diversified business model in the MENA region — setting the benchmark for quality and innovation.
We are committed to providing our customers with high-quality products to grant them the quality of life they deserve — because health is not a luxury, it's a right.
Actively contributing to Saudi Arabia's Vision 2030 by increasing life expectancy, promoting preventive care, and reducing infectious diseases across the Kingdom.
A comprehensive, diversified healthcare model built to serve patients, practitioners, and partners across the region.
Comprehensive range of pharmaceutical products including sterile injectables, tablets, capsules, liquids, and semi-solids for human medicinal use.
High-quality veterinary pharmaceutical products supporting animal health and productivity across livestock, poultry, and companion animals.
Specialized infection control and cosmetics products designed to combat healthcare-associated infections and support public health safety.
Over 36,000 m² of cutting-edge manufacturing space across 3 facilities — delivering 921+ million units annually.
SPI's flagship manufacturing facility hosts 2 dedicated production lines for Human Medicinal Products and Veterinary Medicinal Products, supported by 2 warehouses ensuring seamless supply chain operations.
A dedicated, highly specialized block for cephalosporin antibiotic manufacturing — one of the most sophisticated and controlled pharmaceutical production environments in the region.
A versatile general pharmaceutical manufacturing block capable of producing a broad range of dosage forms including advanced delivery systems like pre-filled syringes and ophthalmic products.
Established in 2001, SPI's world-class R&D center is home to 30+ research scientists pushing the frontiers of pharmaceutical formulation. Our multi-disciplinary team develops differentiated products using cutting-edge enabling technologies.
Every product released only after rigorous analysis, meeting international standards and regulatory requirements.
Quality Management System assessed and certified to ISO 13485:2016 standards for Medical Devices & Products Manufacturing — ensuring international quality benchmarks.
Authorized by the Saudi Food and Drug Authority to produce and export registered pharmaceutical products, fully compliant with Current Good Manufacturing Practices.
Licensed by SFDA to operate in the field of Medical Devices & Products — validating our quality systems, safety protocols, and regulatory compliance framework.
SPI's total corporate sales reached SAR 206.1 Million in 2025 — an 84% increase over 2021.
SPI exports its products to GCC countries (UAE, Oman, Kuwait & Bahrain), Yemen, Iraq, Jordan, Egypt, Libya, and Algeria — with active plans to expand into new global markets in line with Vision 2030.
Ambitious growth targets that align with the Kingdom's healthcare transformation agenda.
Establishing 3 new state-of-the-art manufacturing facilities in Saudi Arabia, expanding our production capacity and geographic reach within the Kingdom.
Expanding our regional and global presence into new markets, building on our existing footprint across 12+ countries in the MENA region.
Launching 100 new pharmaceutical products by 2030, driven by our R&D center and research pipeline across all three business divisions.
Ranking among the Top 5 pharmaceutical companies in KSA — with an upcoming IPO on Tadawul (Saudi Stock Exchange) — driven by quality, innovation, and operational excellence.